Target intelligence / Profile preview

Poliovirus type 2 capsid D-antigen (PV2 D-antigen)

Target
PV2 D-antigen
Molecular classification
Viral capsid protein, Antigen
01

Overview

The Poliovirus type 2 capsid D-antigen is the native, immunogenic form of the viral protein shell required for the induction of protective neutralizing antibodies. It consists of an icosahedral arrangement of 60 copies each of the structural proteins VP1, VP2, VP3, and VP4, which encapsulate the viral RNA genome. The D (dense) state is characterized by its ability to bind to the poliovirus receptor (CD155) and its high stability compared to the C (coreless) antigen, which represents a non-infectious, altered conformation. In the context of vaccine development, the D-antigen is the critical component of the Inactivated Poliovirus Vaccine (IPV), where its concentration is measured in D-antigen units (DU) to ensure potency. Therapeutic and prophylactic strategies focus on maintaining these specific epitopes to elicit a robust immune response, as the loss of D-antigenicity results in a significant reduction in vaccine efficacy.

Other names
Poliovirus type 2 D-antigenPV2 D-antigenPoliovirus type 2 native antigenPoliovirus type 2 capsid protein epitopes
02

Mechanism of action

Induction of neutralizing antibodies that bind to the D-antigen epitopes to prevent viral attachment and entry into host cells.

03

Biological functions

Viral entryViral assemblyImmune recognition
04

Disease associations

PoliomyelitisInfection
05

Safety considerations

Vaccine-derived poliovirus (VDPV) emergenceReversion to neurovirulence (OPV)Incomplete inactivation (IPV)
06

Interacting drugs

Inactivated poliovirus vaccine (IPV)

3 more in the full profile.

07

Biomarkers

D-antigen content (ELISA)Neutralizing antibody titer

Beyond the preview

Go deeper on Poliovirus type 2 capsid D-antigen (PV2 D-antigen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Poliovirus type 2 capsid D-antigen (PV2 D-antigen).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call